BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

PRR11 and SKA2 Gene Pair is Overexpressed and Regulated by p53 in Breast Cancer
Youquan Bu1,*, Yitao Wang1, Chunxue Zhang2, Li Mai3, Yulong Niu4, Yingxiong Wang5
1Department of Biochemistry and Molecular Biology, Chongqing Medical University, Chongqing 400016,China,
2 Laboratory of Birth Defects and Related Diseases of Women and Children, West China Second University Hospital, Sichuan University,Chengdu 610000,China,
3Department of Clinical Laboratory, the Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China,
4Laboratory of Reproductive Biology, School of Public Health, Chongqing Medical University, China
Our previous study found that two novel cancer-related genes PRR11 and SKA2 constitute a classic gene pair that is regulated by p53 and NF-Y in lung cancer. However, their role and regulatory mechanism in breast cancer remain elusive. In this study, we found that the expression levels of PRR11 and SKA2 are upregulated and have a negative prognosis value in breast cancer. Loss-of-function experiments showed that RNAi-mediated knockdown of PRR11 and/or SKA2 inhibits proliferation, migration and invasion of breast cancer cells. Mechanistic experiments revealed that knockdown of PRR11 and/or SKA2 causes dysregulation of several downstream genes including CDK6, TPM3, USP12, etc. Luciferase reporter assay demonstrated that wild type p53 significantly represses the PRR11-SKA2 bidirectional promoter activity whereas not NF-Y. Intriguingly, NF-Y is only essential for and correlated with the expression of PRR11 but not SKA2. Consistently, adriamycin-induced (ADR) activation of endogenous p53 also causes significant repression of PRR11 and SKA2 gene pair expression. Notably, breast cancer patients with lower expression levels of either PRR11 or SKA2 along with wild type p53 exhibit better disease-free survival compared with others with p53 mutation and/or higher expression levels of either PRR11 or SKA2. Collectively, our study indicates that the PRR11 and SKA2 transcription unit might be an oncogenic contributor and serves as a novel diagnostic and therapeutic target in breast cancer.
Abstract, Accepted Manuscript(in press) [Submitted on September 7, 2018, Accepted on December 31, 2018]
  Copyright © KSBMB. All rights reserved. / Powered by, Ltd